| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $34,997,778 ) (Continued on the next page) |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01MD021106 | Integrating molecular and social exposures to understand accelerated aging in cancer patients with HIV in the Southeastern US | 000 | 1 | NIH | 8/5/2026 | $811,939 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA302981 | Fragment-based targeting of EMT-mediated resistance in EGFR-mutant lung cancer | 000 | 1 | NIH | 5/19/2026 | $433,256 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R00CA296780 | The role of oral microbiota in metastatic brain tumors | 000 | 3 | NIH | 6/30/2026 | $248,999 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA312387 | Ketogenic metabolic therapy as therapeutic adjunct in patients undergoing immune checkpoint inhibition therapy for non-small cell lung cancer | 000 | 1 | NIH | 6/23/2026 | $432,473 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K99CA300504 | Engineering antigen-specific tumor-infiltrating lymphocytes for adoptive cell therapy of HNSCC | 000 | 1 | NIH | 7/9/2026 | $119,597 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA299434 | Defining the role of MAFG in melanocyte transformation and melanoma development | 000 | 1 | NIH | 4/6/2026 | $607,249 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | T32CA090314 | Behavioral Oncology Education & Career Development | 000 | 23 | NIH | 8/7/2026 | $402,837 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA305812 | Harnessing big data to understand the confluence of HIV and cancer stigma in the US Southeast | 000 | 2 | NIH | 8/6/2026 | $802,252 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21AG100933 | Deciphering the contribution of the aged alveolar niche to lung cancer evolution | 000 | 1 | NIH | 6/11/2026 | $463,375 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA309659 | Cysteine Acquisition and Utilization in Lung Adenocarcinoma | 000 | 1 | NIH | 5/13/2026 | $687,593 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | F31CA310579 | Targeting mitochondrial stress responses in melanoma to enhance immunotherapy | 000 | 1 | NIH | 5/1/2026 | $40,393 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA299472 | Aging, DNA methylation, and incident cardiovascular disease in breast cancer survivors | 000 | 2 | NIH | 7/14/2026 | $655,534 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA293755 | Program control of CD8+ T cell response to tumors and tumor memory | 000 | 2 | NIH | 5/1/2026 | $549,460 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA315693 | Targeting branched-chain keto acid accumulation in melanoma leptomeningeal disease | 000 | 1 | NIH | 7/29/2026 | $694,309 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA276496 | Body composition and adiposity-associated thromboinflammation in colorectal cancer prognosis | 000 | 3 | NIH | 5/4/2026 | $664,357 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K99CA304508 | Mechanisms of dormant breast cancer cell communication with their environment | 000 | 2 | NIH | 6/23/2026 | $123,182 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279713 | RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing | 000 | 4 | NIH | 4/6/2026 | $441,529 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA278300 | The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia | 000 | 4 | NIH | 2/27/2026 | $495,033 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA269721 | Role of ULK3 in Sensitive and Refractory Multiple Myeloma | 001 | 4 | NIH | 4/16/2026 | $53,438 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA269721 | Role of ULK3 in Sensitive and Refractory Multiple Myeloma | 000 | 4 | NIH | 12/9/2025 | $480,943 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA275974 | Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | 001 | 4 | NIH | 4/20/2026 | $65,716 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA275974 | Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | 000 | 4 | NIH | 2/10/2026 | $591,443 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01DE033329 | Biomarker Approach to Screening for the early detection of HPV-related Oropharyngeal Cancer (BASH OPC) | 001 | 4 | NIH | 7/22/2026 | $707,563 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA276939 | Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma | 000 | 3 | NIH | 6/19/2026 | $669,302 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA200464 | Quantitative Imaging Clinical Validation Center at Moffitt Cancer Center | 001 | 9 | NIH | 8/11/2026 | $1,322,710 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM155298 | Dissecting enhancer function through integrative genomics | 000 | 3 | NIH | 7/10/2026 | $421,250 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | P30CA076292 | Moffitt Cancer Center Support Grant | 000 | 28 | NIH | 5/26/2026 | $4,054,822 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA281756 | Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy | 001 | 3 | NIH | 7/15/2026 | $2,068,249 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01NS135220 | Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3 | 001 | 3 | NIH | 3/5/2026 | $62,113 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01NS135220 | Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3 | 000 | 3 | NIH | 12/11/2025 | $559,022 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K99CA315379 | Leveraging non-canonical role of CDK9 to Target CCNE1-amplified high-grade serous ovarian cancer | 000 | 1 | NIH | 7/21/2026 | $109,107 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA292692 | Interrogating the relationship between translational dynamics and non-canonical antigen presentation in lung cancer | 001 | 3 | NIH | 7/8/2026 | $1,448,091 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA280116 | MYC-alarmin axis as a novel therapeutic vulnerability in myelofibrosis | 001 | 3 | NIH | 6/26/2026 | $1,659,122 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279378 | Selective targeting of TAF1 function in acute myeloid leukemia | 001 | 3 | NIH | 4/16/2026 | $67,835 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279378 | Selective targeting of TAF1 function in acute myeloid leukemia | 000 | 3 | NIH | 1/16/2026 | $610,534 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K99GM154063 | Dual E3 ligase function of TRIM25 in modulating innate immunity | 001 | 2 | NIH | 3/10/2026 | $113,234 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM165628 | Regulation of Selenium Metabolism and Selenoprotein Synthesis | 000 | 1 | NIH | 7/23/2026 | $421,250 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA262483 | Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma | 000 | 5 | NIH | 6/30/2026 | $481,119 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA255398 | Characterizing oncogenic function of ITCH in melanoma | 000 | 6 | NIH | 6/26/2026 | $357,913 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA244328 | Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison | 000 | 5 | NIH | 7/8/2026 | $1,044,728 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA260356 | Anti-tumor potential of temperature-sensitive p53 mutants | 000 | 6 | NIH | 2/27/2026 | $444,589 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | T32CA233399 | Integrated Program in Cancer and Data Science (ICADS) | 001 | 6 | NIH | 7/6/2026 | $122,540 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R50CA211447 | Developing chemical probes for oncogenic signaling pathways | 000 | 9 | NIH | 8/19/2026 | $293,933 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA299480 | The MIND-BC Study: MIND diet for Breast cancer Cognition | 000 | 2 | NIH | 3/19/2026 | $696,013 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | 001 | 7 | NIH | 3/10/2026 | $46,337 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | 000 | 7 | NIH | 1/22/2026 | $417,038 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DE034377 | Ultrasensitive detection of circulating DNA methylation for head and neck cancer prognosis | 000 | 2 | NIH | 6/11/2026 | $712,674 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R34CA297368 | Libre Del Cigarrillo: Development of an mHealth Smoking Cessation App to Extend Reach of a Validated Smoking Cessation Intervention for Spanish-speaking Smokers | 000 | 2 | NIH | 5/14/2026 | $312,790 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | UG1HL108987 | Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1 | 000 | 16 | NIH | 8/14/2026 | $214,179 |
|
